Summary

The global Veterinary Vaccine market is projected to grow from US$ 13284 million in 2025 to US$ 21194 million by 2032, at a CAGR of 6.9% (2026-2032), driven by critical product segments and diverse end‑use applications.
Veterinary Vaccine refers to a biological preparation designed to stimulate protective immune responses in animals against specific infectious diseases. These vaccines contain antigens derived from pathogens or produced through biological and molecular technologies, enabling the animal immune system to develop pathogen-specific immunity and reduce the incidence, severity, or transmission of infectious diseases. Veterinary vaccines are administered through injection, oral delivery, intranasal application, drinking water, spray, or other veterinary-approved routes, depending on the target species and disease characteristics. Their effectiveness is determined by antigen quality, immunogenicity, protective efficacy, safety, duration of immunity, and compatibility with animal health management programs. Veterinary vaccines are essential preventive biological products used in veterinary medicine, livestock disease control, companion animal healthcare, and aquatic animal health management.
Key Findings
Veterinary Vaccine demand is structurally supported by livestock disease prevention, companion animal healthcare, and animal health management requirements
The Veterinary Vaccine market comprises live attenuated, inactivated, recombinant, nucleic acid, and other vaccine technologies
Veterinary Vaccine applications in swine and poultry farming represent important commercial demand segments
Veterinary Vaccine development increasingly emphasizes recombinant technologies, improved vaccine safety, and more efficient immunization programs
Veterinary Vaccine regional markets differ substantially in disease epidemiology, vaccination regulations, livestock production systems, and purchasing practices
Market Trends
The veterinary vaccine industry is undergoing a gradual transition from conventional disease-specific immunization toward more sophisticated preventive healthcare solutions integrating advanced antigen technologies, improved delivery systems, and comprehensive disease management programs. Live attenuated and inactivated vaccines remain fundamental technologies because of their established manufacturing processes, regulatory experience, and broad applications in commercial animal production. Meanwhile, recombinant vaccines, including subunit and vector-based technologies, are attracting greater attention for their potential to improve antigen specificity, safety profiles, and compatibility with disease surveillance strategies. Nucleic acid technologies represent an additional development direction, although their commercial adoption remains dependent on species-specific efficacy, delivery methods, regulatory approval, and manufacturing economics. Another important trend is the increasing emphasis on vaccination convenience, particularly through mass-administration methods in poultry production and optimized immunization schedules in large-scale livestock operations. Vaccine manufacturers are also developing products with improved stability, longer-lasting immunity, and compatibility with combination vaccination programs. These developments indicate that competitive differentiation is increasingly influenced by practical disease protection, vaccination efficiency, and measurable animal health outcomes rather than antigen technology alone.
Market Dynamics
Drivers
Veterinary vaccine demand is supported by the economic consequences of infectious animal diseases, increasing attention to livestock biosecurity, and the continuing professionalization of animal production systems. Disease outbreaks can cause mortality, reduced productivity, movement restrictions, and disruptions to animal product supply chains, creating incentives for preventive immunization where effective vaccines are available. Commercial swine, poultry, and cattle producers increasingly evaluate vaccination as part of integrated herd and flock health management. Companion animal vaccination is additionally supported by preventive veterinary care, pet ownership, and routine immunization recommendations. Government-supported disease control programs and veterinary regulatory frameworks also influence vaccine utilization, particularly for diseases associated with animal trade, public health, or national livestock protection.
Restraints
Veterinary vaccine adoption is constrained by differences in animal disease prevalence, vaccination economics, and the operational capabilities of end users. Livestock producers are sensitive to vaccine acquisition costs, administration expenses, labor requirements, and the expected economic benefit of disease prevention. Vaccine effectiveness may vary with pathogen strains, maternal antibodies, animal health status, and vaccination practices, requiring continuous technical support and product evaluation. Temperature-sensitive distribution, biological manufacturing complexity, and regulatory requirements can increase operating costs. In certain markets, limited veterinary infrastructure and inconsistent vaccination coverage restrict the commercialization of advanced products, while disease-specific vaccination policies can significantly influence purchasing volumes.
Opportunities
Commercial opportunities are emerging in vaccines addressing economically important diseases for which existing prevention methods provide incomplete protection, as well as in improved formulations that simplify vaccination and reduce administration costs. Recombinant antigen technologies, multivalent formulations, and optimized adjuvant systems provide potential routes for product differentiation where supported by demonstrated efficacy and regulatory approval. Large-scale poultry and swine production creates opportunities for vaccines compatible with automated or group-level administration. Aquaculture vaccination and specialized companion animal immunization offer additional product development opportunities based on species-specific disease requirements. Manufacturers capable of combining local pathogen surveillance, clinical development, regulatory expertise, and reliable supply may strengthen their position in regional markets.
Challenges
The veterinary vaccine industry faces persistent challenges associated with pathogen evolution, biological product development, and commercialization across heterogeneous animal populations. Emerging pathogen variants may reduce the effectiveness of existing vaccine strains, requiring antigen updates, additional efficacy studies, or revised vaccination strategies. Development programs must establish acceptable safety and protection under relevant field conditions, while production requires consistent antigen quality and validated manufacturing processes. Regulatory approval procedures vary across jurisdictions, creating additional complexity for international commercialization. Manufacturers also face the risk that successful disease control, changes in vaccination policy, or shifts in livestock production can alter demand for individual vaccines. Maintaining manufacturing quality, reliable distribution, and economically sustainable product portfolios therefore remains central to long-term competitiveness.
Industry Chain Analysis
The veterinary vaccine industry chain consists of upstream biological materials and manufacturing inputs, midstream vaccine research and production, and downstream veterinary distribution and immunization services. Upstream activities include pathogen strain development, antigen production systems, cell culture media, biological reagents, adjuvants, stabilizers, packaging materials, and specialized manufacturing equipment. The choice of production technology determines the requirements for biological substrates, antigen purification, formulation, and quality control. Midstream manufacturers undertake strain selection, antigen development, process optimization, formulation, aseptic processing, filling, quality testing, and regulatory registration. Biological consistency, contamination control, antigen potency, and manufacturing yield directly influence production economics and product reliability.
Downstream distribution involves veterinary pharmaceutical channels, animal health service providers, livestock production enterprises, veterinary clinics, and government disease prevention programs. Cold-chain transportation and inventory management are important for maintaining product integrity where temperature-controlled storage is required. The industry's value creation is concentrated not only in manufacturing but also in antigen technology, clinical efficacy validation, regulatory capabilities, and disease-specific technical services. Products addressing important diseases with differentiated protection, convenient administration, or strong field performance may support higher added value, while mature vaccines often face greater procurement and price competition. Manufacturers with integrated research, production, quality management, and distribution capabilities can improve supply reliability and respond more effectively to regional disease control requirements.
Segment Insights
By vaccine technology, live attenuated vaccines and inactivated vaccines constitute established commercial categories in the veterinary vaccine market. Live attenuated vaccines use weakened pathogens capable of inducing immune responses and are widely applied where strong immune stimulation and suitable administration methods are important. Their commercial performance depends on genetic stability, safety, storage requirements, and the balance between immunogenicity and residual biological risk. Inactivated vaccines use noninfectious pathogen antigens and are important in livestock and companion animal immunization programs, often requiring carefully designed formulations and adjuvant systems to achieve the desired immune response. These conventional technologies benefit from established production infrastructure and extensive practical experience, although antigen production costs, booster requirements, and strain matching remain important considerations.
Recombinant veterinary vaccines represent a technologically differentiated segment encompassing recombinant subunit, vector-based, and related antigen production approaches. Their value proposition includes targeted antigen design, potential safety advantages, and opportunities to support differentiation between infected and vaccinated animals when appropriately designed. Commercial development requires effective antigen expression, suitable immune stimulation, and competitive manufacturing costs. Nucleic acid vaccines represent a more emerging segment, with development focused on antigen expression efficiency, delivery technologies, formulation stability, and species-specific protective efficacy. From the perspective of target animals, swine and poultry vaccines are important commercial segments because of intensive production systems, concentrated animal populations, and recurring disease prevention requirements. Companion animal vaccines are differentiated by veterinary clinical channels, individual animal health management, and established preventive care schedules. Across these segments, opportunities arise from improved vaccine efficacy, convenient administration, broader disease protection, and products addressing unmet disease prevention needs.
Downstream Market Opportunities
Swine farming and poultry farming are two strategically important downstream applications for veterinary vaccines. In swine production, vaccines are incorporated into breeding herd, piglet, and growing-finishing health programs to manage infectious diseases that affect reproductive performance, survival, and production efficiency. Producers evaluate vaccine efficacy against circulating pathogens, duration of immunity, compatibility with existing immunization schedules, and the operational cost of administration. Large integrated swine producers may favor suppliers capable of providing consistent product quality, disease monitoring support, and coordinated vaccination programs across multiple production facilities. In poultry farming, vaccines are administered at hatcheries and farms through injection, spray, drinking water, or other approved methods. The large number of animals and short production cycles in commercial poultry systems make vaccination throughput, uniform coverage, labor efficiency, and protection during critical production stages especially important. Products compatible with hatchery automation or simplified flock-level administration can create measurable operational value.
Cattle farming and companion animal healthcare represent additional differentiated opportunities. In cattle production, vaccination programs address respiratory, reproductive, and other infectious diseases affecting dairy and beef production, with purchasing decisions influenced by herd management practices, animal value, and expected disease-related losses. Combination vaccines and vaccination schedules aligned with breeding or production cycles may improve operational efficiency. In companion animal healthcare, vaccines are administered through veterinary clinics as part of routine preventive medicine, with demand influenced by veterinary recommendations, animal age, lifestyle, disease exposure, and local vaccination requirements. Manufacturers can pursue opportunities through differentiated formulations, convenient vaccination schedules, and expanded veterinary clinical coverage. Aquaculture represents a specialized opportunity where vaccines must match the biology of farmed species, aquatic pathogens, and practical administration conditions. Across downstream markets, sustainable growth depends on demonstrated protection, cost-effective delivery, and alignment with the operational requirements of animal owners and producers.
Regional Insights
North America and Europe are established veterinary vaccine markets characterized by developed veterinary healthcare infrastructure, established regulatory systems, and substantial commercial livestock and companion animal healthcare activities. In North America, large-scale cattle, swine, and poultry production supports demand for preventive biological products, while companion animal vaccination benefits from established veterinary clinical services. European demand is shaped by intensive livestock production in major agricultural economies, structured animal health management, and regulatory requirements governing vaccine authorization and disease prevention. The region also supports development of differentiated veterinary biological technologies, although national disease control policies and livestock production structures create differences among individual markets.
Asia-Pacific represents an important production and consumption region, with China, Japan, and other major livestock-producing economies exhibiting distinct market characteristics. China's substantial swine and poultry industries support broad commercial demand, while domestic vaccine manufacturers play an important role in product supply and disease prevention programs. Japan has an established veterinary healthcare market with emphasis on product quality, regulatory compliance, and specialized animal health applications. Other Asian markets offer opportunities associated with modernization of livestock production, improved veterinary infrastructure, and expansion of preventive disease management. Latin America is influenced by extensive cattle production and major poultry and swine industries, while markets in the Middle East and Africa exhibit varied vaccination coverage, veterinary infrastructure, and disease control priorities. Regional commercial opportunities depend on pathogen prevalence, local registration requirements, affordability, distribution capabilities, and alignment with government and producer-led vaccination programs.
Report Scope
This definitive report equips business leaders, decision-makers, and stakeholders with a 360° view of the global Veterinary Vaccine market, seamlessly integrating production and sales performance across the value chain. It analyzes historical sales volume and revenue sales data (2021–2025) and delivers forecasts through 2032, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies volume and value, growth rates, technical innovations, niche opportunities, and substitution risks, and analyzes downstream customer distribution pattern.
Granular regional insights cover five major markets (North America, Europe, APAC, South America, and MEA) with in‑depth analysis of 20+ countries. Each region’s dominant products, competitive landscape, and downstream demand trends are clearly detailed.
Critical competitive intelligence profiles manufacturers (sales volume, revenue, margins, pricing strategies, and major customers) and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise supply‑chain overview maps upstream suppliers, manufacturing technologies, cost structures, and distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation
By Company
Merck
Zoetis
Boehringer Ingelheim
Ceva
CAHIC
HVRI
Ringpu Biology
Yebio
DHN
WINSUN
Elanco
Virbac
Jinyu Bio-Technology
ChengDu Tecbond
CAVAC
Kyoto Biken Laboratories
FATRO
Vaksindo
Bio-Labs
Avimex Animal Health
MEVAC
Biovac
Atafen
Dyntec
RVSRI
Medion
Segment by Type
Live Attenuated Vaccines
Inactivated Vaccines
Other
Segment by Target Pathogen
Viral Vaccines
Bacterial Vaccines
Parasitic Vaccines
Other
Segment by Antigen Composition
Monovalent Vaccines
Multivalent Vaccines
Combination Vaccines
Segment by Application
Farm Animal
Companion Animal
Sales by Region
North America
U.S.
Canada
Mexico
Asia-Pacific
China
Japan
South Korea
India
China Taiwan
Southeast Asia (Indonesia, Vietnam, Thailand)
Europe
Germany
France
U.K.
Italy
Russia
Greece
Ukraine
Moldova
Albania
Serbia
Central and South America
Brazil
Argentina
Rest of Central and South America
Middle East, Africa
Turkey
Egypt
GCC Countries
South Africa
Chapter Outline
Chapter 1: Defines the Veterinary Vaccine study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential
Chapter 2: Offers current market state, projects global revenue and sales to 2032, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the manufacturer landscape: ranks by volume and revenue, analyzes profitability and pricing, maps production bases, details manufacturer performance by product type and evaluates concentration alongside M&A moves
Chapter 4: Unlocks high margin product segments: compares sales, revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities: evaluates sales, revenue, and pricing by Application, identifies emerging use cases, and profiles leading customers by region and by Application
Chapter 6: North America: breaks down sales and revenue by Application and country, profiles key manufacturers and assesses growth drivers and barriers
Chapter 7: Europe: analyses regional sales, revenue and market by Application and manufacturers, flagging drivers and barriers
Chapter 8: Asia Pacific: quantifies sales and revenue by Application, and region/country, profiles top manufacturers, and uncovers high potential expansion areas
Chapter 9: Central & South America: measures sales and revenue by Application, and country, profiles top manufacturers, and identifies investment opportunities and challenges
Chapter 10: Middle East and Africa: evaluates sales and revenue by Application, and country, profiles key manufacturers, and outlines investment prospects and market hurdles
Chapter 11: Profiles manufacturers in depth: details product specs, sales, revenue, margins; top manufactures 2025 sales breakdowns by product type, by Application, by sales region SWOT analysis, and recent strategic developments
Chapter 12: Supply chain: analyses upstream raw materials and suppliers, manufacturing footprint, regional production and cost, regulatory and technology, plus downstream channels and distributor roles
Chapter 13: Market dynamics: explores drivers, restraints, regulatory impacts, and risk mitigation strategies
Chapter 14: Actionable conclusions and strategic recommendations.
Why This Report
Beyond standard market data, this analysis provides a clear profitability roadmap, empowering you to:
Allocate capital strategically to high growth regions (Chapters 6-10) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 12) and customers (Chapter 5) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
Secure your supply chain against disruptions through upstream and downstream visibility (Chapters 12 and 13).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.

ページTOPに戻る

Table of Contents

1 Study Coverage
1.1 Introduction to Veterinary Vaccine: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Veterinary Vaccine Market Size by Type, 2021 vs 2025 vs 2032
1.2.2 Live Attenuated Vaccines
1.2.3 Inactivated Vaccines
1.2.4 Other
1.3 Market Segmentation by Target Pathogen
1.3.1 Global Veterinary Vaccine Market Size by Target Pathogen, 2021 vs 2025 vs 2032
1.3.2 Viral Vaccines
1.3.3 Bacterial Vaccines
1.3.4 Parasitic Vaccines
1.3.5 Other
1.4 Market Segmentation by Antigen Composition
1.4.1 Global Veterinary Vaccine Market Size by Antigen Composition, 2021 vs 2025 vs 2032
1.4.2 Monovalent Vaccines
1.4.3 Multivalent Vaccines
1.4.4 Combination Vaccines
1.5 Market Segmentation by Application
1.5.1 Global Veterinary Vaccine Market Size by Application, 2021 vs 2025 vs 2032
1.5.2 Farm Animal
1.5.3 Companion Animal
1.6 Assumptions and Limitations
1.7 Study Objectives
1.8 Years Considered

2 Executive Summary
2.1 Global Veterinary Vaccine Revenue Estimates and Forecasts (2021-2032)
2.2 Global Veterinary Vaccine Revenue by Region
2.2.1 Revenue Comparison: 2021 vs 2025 vs 2032
2.2.2 Historical and Forecasted Revenue by Region (2021-2032)
2.2.3 Global Revenue-Based Market Share by Region (2021-2032)
2.3 Global Veterinary Vaccine Sales Estimates and Forecasts (2021-2032)
2.4 Global Veterinary Vaccine Sales by Region
2.4.1 Sales Comparison: 2021 vs 2025 vs 2032
2.4.2 Historical and Forecasted Sales by Region (2021-2032)
2.4.3 Emerging Market Focus: Growth Drivers & Investment Trends
2.4.4 Global Sales Market Share by Region (2021-2032)

3 Competitive Landscape
3.1 Global Veterinary Vaccine Sales by Manufacturers
3.1.1 Global Sales Volume by Manufacturers (2021-2026)
3.1.2 Global Top 5 and Top 10 Manufacturers’Market Share by Sales Volume (2025)
3.2 Global Veterinary Vaccine Manufacturer Revenue Rankings and Tiers
3.2.1 Global Revenue (Value) by Manufacturers (2021-2026)
3.2.2 Global Key Manufacturer Revenue Ranking (2024 vs. 2025)
3.2.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.3 Manufacturer Profitability Profiles and Pricing Strategies
3.3.1 Gross Margin by Top Manufacturer (2021 vs 2025)
3.3.2 Manufacturer-Level Price Trends (2021-2026)
3.4 Key Manufacturers Manufacturing Base and Headquarters
3.5 Key Manufacturers Market Share by Product Type
3.5.1 Live Attenuated Vaccines: Market Share by Key Manufacturers
3.5.2 Inactivated Vaccines: Market Share by Key Manufacturers
3.5.3 Other: Market Share by Key Manufacturers
3.6 Global Veterinary Vaccine Market Concentration and Dynamics
3.6.1 Global Market Concentration
3.6.2 Entrant/Exit Impact Analysis
3.6.3 Strategic Moves: M&A, Capacity Expansion, R&D Investment

4 Product Segmentation
4.1 Global Veterinary Vaccine Sales Performance by Type
4.1.1 Global Veterinary Vaccine Sales Volume by Type (2021-2032)
4.1.2 Global Veterinary Vaccine Revenue by Type (2021-2032)
4.1.3 Global Average Selling Price (ASP) Trends by Type (2021-2032)
4.2 Global Veterinary Vaccine Sales Performance by Target Pathogen
4.2.1 Global Veterinary Vaccine Sales Volume by Target Pathogen (2021-2032)
4.2.2 Global Veterinary Vaccine Revenue by Target Pathogen (2021-2032)
4.2.3 Global Average Selling Price (ASP) Trends by Target Pathogen (2021-2032)
4.3 Global Veterinary Vaccine Sales Performance by Antigen Composition
4.3.1 Global Veterinary Vaccine Sales Volume by Antigen Composition (2021-2032)
4.3.2 Global Veterinary Vaccine Revenue by Antigen Composition (2021-2032)
4.3.3 Global Average Selling Price (ASP) Trends by Antigen Composition (2021-2032)
4.4 Product Technology Differentiation
4.5 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.5.1 High-Growth Niches and Adoption Drivers
4.5.2 Profitability Hotspots and Cost Drivers
4.5.3 Substitution Threats

5 Downstream Applications and Customers
5.1 Global Veterinary Vaccine Sales by Application
5.1.1 Global Historical and Forecasted Sales by Application (2021-2032)
5.1.2 Global Sales Market Share by Application (2021-2032)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Global Veterinary Vaccine Revenue by Application
5.2.1 Global Historical and Forecasted Revenue by Application (2021-2032)
5.2.2 Revenue-Based Market Share by Application (2021-2032)
5.3 Global Pricing Dynamics by Application (2021-2032)
5.4 Downstream Customer Analysis
5.4.1 Top Customers by Region
5.4.2 Top Customers by Application

6 North America
6.1 North America Sales Volume and Revenue (2021-2032)
6.2 North America Key Manufacturers Sales Revenue in 2025
6.3 North America Veterinary Vaccine Sales and Revenue by Application (2021-2032)
6.4 North America Growth Accelerators and Market Barriers
6.5 North America Veterinary Vaccine Market Size by Country
6.5.1 North America Revenue by Country
6.5.2 North America Sales Trends by Country
6.5.3 US
6.5.4 Canada
6.5.5 Mexico

7 Europe
7.1 Europe Sales Volume and Revenue (2021-2032)
7.2 Europe Key Manufacturers Sales Revenue in 2025
7.3 Europe Veterinary Vaccine Sales and Revenue by Application (2021-2032)
7.4 Europe Growth Accelerators and Market Barriers
7.5 Europe Veterinary Vaccine Market Size by Country
7.5.1 Europe Revenue by Country
7.5.2 Europe Sales Trends by Country
7.5.3 Germany
7.5.4 France
7.5.5 U.K.
7.5.6 Italy
7.5.7 Russia
7.5.8 Greece
7.5.9 Ukraine
7.5.10 Moldova
7.5.11 Albania
7.5.12 Serbia

8 Asia-Pacific
8.1 Asia-Pacific Sales Volume and Revenue (2021-2032)
8.2 Asia-Pacific Key Manufacturers Sales Revenue in 2025
8.3 Asia-Pacific Veterinary Vaccine Sales and Revenue by Application (2021-2032)
8.4 Asia-Pacific Veterinary Vaccine Market Size by Region
8.4.1 Asia-Pacific Revenue by Region
8.4.2 Asia-Pacific Sales Trends by Region
8.5 Asia-Pacific Growth Accelerators and Market Barriers
8.6 Southeast Asia
8.6.1 Southeast Asia Revenue by Country (2021 vs 2025 vs 2032)
8.6.2 Key Country Analysis: Indonesia, Vietnam, Thailand, Malaysia, Philippines
8.7 China
8.8 Japan
8.9 South Korea
8.10 China Taiwan
8.11 India

9 Central and South America
9.1 Central and South America Sales Volume and Revenue (2021-2032)
9.2 Central and South America Key Manufacturers Sales Revenue in 2025
9.3 Central and South America Veterinary Vaccine Sales and Revenue by Application (2021-2032)
9.4 Central and South America Investment Opportunities and Key Challenges
9.5 Central and South America Veterinary Vaccine Market Size by Country
9.5.1 Central and South America Revenue Trends by Country (2021 vs 2025 vs 2032)
9.5.2 Brazil
9.5.3 Argentina

10 Middle East and Africa
10.1 Middle East and Africa Sales Volume and Revenue (2021-2032)
10.2 Middle East and Africa Key Manufacturers Sales Revenue in 2025
10.3 Middle East and Africa Veterinary Vaccine Sales and Revenue by Application (2021-2032)
10.4 Middle East and Africa Investment Opportunities and Key Challenges
10.5 Middle East and Africa Veterinary Vaccine Market Size by Country
10.5.1 Middle East and Africa Revenue Trends by Country (2021 vs 2025 vs 2032)
10.5.2 GCC Countries
10.5.3 Turkey
10.5.4 Egypt
10.5.5 South Africa

11 Corporate Profile
11.1 Merck
11.1.1 Merck Corporation Information
11.1.2 Merck Business Overview
11.1.3 Merck Veterinary Vaccine Product Models, Descriptions and Specifications
11.1.4 Merck Veterinary Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
11.1.5 Merck Veterinary Vaccine Sales by Product in 2025
11.1.6 Merck Veterinary Vaccine Sales by Application in 2025
11.1.7 Merck Veterinary Vaccine Sales by Geographic Area in 2025
11.1.8 Merck Veterinary Vaccine SWOT Analysis
11.1.9 Merck Recent Developments
11.2 Zoetis
11.2.1 Zoetis Corporation Information
11.2.2 Zoetis Business Overview
11.2.3 Zoetis Veterinary Vaccine Product Models, Descriptions and Specifications
11.2.4 Zoetis Veterinary Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
11.2.5 Zoetis Veterinary Vaccine Sales by Product in 2025
11.2.6 Zoetis Veterinary Vaccine Sales by Application in 2025
11.2.7 Zoetis Veterinary Vaccine Sales by Geographic Area in 2025
11.2.8 Zoetis Veterinary Vaccine SWOT Analysis
11.2.9 Zoetis Recent Developments
11.3 Boehringer Ingelheim
11.3.1 Boehringer Ingelheim Corporation Information
11.3.2 Boehringer Ingelheim Business Overview
11.3.3 Boehringer Ingelheim Veterinary Vaccine Product Models, Descriptions and Specifications
11.3.4 Boehringer Ingelheim Veterinary Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
11.3.5 Boehringer Ingelheim Veterinary Vaccine Sales by Product in 2025
11.3.6 Boehringer Ingelheim Veterinary Vaccine Sales by Application in 2025
11.3.7 Boehringer Ingelheim Veterinary Vaccine Sales by Geographic Area in 2025
11.3.8 Boehringer Ingelheim Veterinary Vaccine SWOT Analysis
11.3.9 Boehringer Ingelheim Recent Developments
11.4 Ceva
11.4.1 Ceva Corporation Information
11.4.2 Ceva Business Overview
11.4.3 Ceva Veterinary Vaccine Product Models, Descriptions and Specifications
11.4.4 Ceva Veterinary Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
11.4.5 Ceva Veterinary Vaccine Sales by Product in 2025
11.4.6 Ceva Veterinary Vaccine Sales by Application in 2025
11.4.7 Ceva Veterinary Vaccine Sales by Geographic Area in 2025
11.4.8 Ceva Veterinary Vaccine SWOT Analysis
11.4.9 Ceva Recent Developments
11.5 CAHIC
11.5.1 CAHIC Corporation Information
11.5.2 CAHIC Business Overview
11.5.3 CAHIC Veterinary Vaccine Product Models, Descriptions and Specifications
11.5.4 CAHIC Veterinary Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
11.5.5 CAHIC Veterinary Vaccine Sales by Product in 2025
11.5.6 CAHIC Veterinary Vaccine Sales by Application in 2025
11.5.7 CAHIC Veterinary Vaccine Sales by Geographic Area in 2025
11.5.8 CAHIC Veterinary Vaccine SWOT Analysis
11.5.9 CAHIC Recent Developments
11.6 HVRI
11.6.1 HVRI Corporation Information
11.6.2 HVRI Business Overview
11.6.3 HVRI Veterinary Vaccine Product Models, Descriptions and Specifications
11.6.4 HVRI Veterinary Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
11.6.5 HVRI Recent Developments
11.7 Ringpu Biology
11.7.1 Ringpu Biology Corporation Information
11.7.2 Ringpu Biology Business Overview
11.7.3 Ringpu Biology Veterinary Vaccine Product Models, Descriptions and Specifications
11.7.4 Ringpu Biology Veterinary Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
11.7.5 Ringpu Biology Recent Developments
11.8 Yebio
11.8.1 Yebio Corporation Information
11.8.2 Yebio Business Overview
11.8.3 Yebio Veterinary Vaccine Product Models, Descriptions and Specifications
11.8.4 Yebio Veterinary Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
11.8.5 Yebio Recent Developments
11.9 DHN
11.9.1 DHN Corporation Information
11.9.2 DHN Business Overview
11.9.3 DHN Veterinary Vaccine Product Models, Descriptions and Specifications
11.9.4 DHN Veterinary Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
11.9.5 DHN Recent Developments
11.10 WINSUN
11.10.1 WINSUN Corporation Information
11.10.2 WINSUN Business Overview
11.10.3 WINSUN Veterinary Vaccine Product Models, Descriptions and Specifications
11.10.4 WINSUN Veterinary Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
11.10.5 WINSUN Recent Developments
11.11 Elanco
11.11.1 Elanco Corporation Information
11.11.2 Elanco Business Overview
11.11.3 Elanco Veterinary Vaccine Product Models, Descriptions and Specifications
11.11.4 Elanco Veterinary Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
11.11.5 Elanco Recent Developments
11.12 Virbac
11.12.1 Virbac Corporation Information
11.12.2 Virbac Business Overview
11.12.3 Virbac Veterinary Vaccine Product Models, Descriptions and Specifications
11.12.4 Virbac Veterinary Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
11.12.5 Virbac Recent Developments
11.13 Jinyu Bio-Technology
11.13.1 Jinyu Bio-Technology Corporation Information
11.13.2 Jinyu Bio-Technology Business Overview
11.13.3 Jinyu Bio-Technology Veterinary Vaccine Product Models, Descriptions and Specifications
11.13.4 Jinyu Bio-Technology Veterinary Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
11.13.5 Jinyu Bio-Technology Recent Developments
11.14 ChengDu Tecbond
11.14.1 ChengDu Tecbond Corporation Information
11.14.2 ChengDu Tecbond Business Overview
11.14.3 ChengDu Tecbond Veterinary Vaccine Product Models, Descriptions and Specifications
11.14.4 ChengDu Tecbond Veterinary Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
11.14.5 ChengDu Tecbond Recent Developments
11.15 CAVAC
11.15.1 CAVAC Corporation Information
11.15.2 CAVAC Business Overview
11.15.3 CAVAC Veterinary Vaccine Product Models, Descriptions and Specifications
11.15.4 CAVAC Veterinary Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
11.15.5 CAVAC Recent Developments
11.16 Kyoto Biken Laboratories
11.16.1 Kyoto Biken Laboratories Corporation Information
11.16.2 Kyoto Biken Laboratories Business Overview
11.16.3 Kyoto Biken Laboratories Veterinary Vaccine Product Models, Descriptions and Specifications
11.16.4 Kyoto Biken Laboratories Veterinary Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
11.16.5 Kyoto Biken Laboratories Recent Developments
11.17 FATRO
11.17.1 FATRO Corporation Information
11.17.2 FATRO Business Overview
11.17.3 FATRO Veterinary Vaccine Product Models, Descriptions and Specifications
11.17.4 FATRO Veterinary Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
11.17.5 FATRO Recent Developments
11.18 Vaksindo
11.18.1 Vaksindo Corporation Information
11.18.2 Vaksindo Business Overview
11.18.3 Vaksindo Veterinary Vaccine Product Models, Descriptions and Specifications
11.18.4 Vaksindo Veterinary Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
11.18.5 Vaksindo Recent Developments
11.19 Bio-Labs
11.19.1 Bio-Labs Corporation Information
11.19.2 Bio-Labs Business Overview
11.19.3 Bio-Labs Veterinary Vaccine Product Models, Descriptions and Specifications
11.19.4 Bio-Labs Veterinary Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
11.19.5 Bio-Labs Recent Developments
11.20 Avimex Animal Health
11.20.1 Avimex Animal Health Corporation Information
11.20.2 Avimex Animal Health Business Overview
11.20.3 Avimex Animal Health Veterinary Vaccine Product Models, Descriptions and Specifications
11.20.4 Avimex Animal Health Veterinary Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
11.20.5 Avimex Animal Health Recent Developments
11.21 MEVAC
11.21.1 MEVAC Corporation Information
11.21.2 MEVAC Business Overview
11.21.3 MEVAC Veterinary Vaccine Product Models, Descriptions and Specifications
11.21.4 MEVAC Veterinary Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
11.21.5 MEVAC Recent Developments
11.22 Biovac
11.22.1 Biovac Corporation Information
11.22.2 Biovac Business Overview
11.22.3 Biovac Veterinary Vaccine Product Models, Descriptions and Specifications
11.22.4 Biovac Veterinary Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
11.22.5 Biovac Recent Developments
11.23 Atafen
11.23.1 Atafen Corporation Information
11.23.2 Atafen Business Overview
11.23.3 Atafen Veterinary Vaccine Product Models, Descriptions and Specifications
11.23.4 Atafen Veterinary Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
11.23.5 Atafen Recent Developments
11.24 Dyntec
11.24.1 Dyntec Corporation Information
11.24.2 Dyntec Business Overview
11.24.3 Dyntec Veterinary Vaccine Product Models, Descriptions and Specifications
11.24.4 Dyntec Veterinary Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
11.24.5 Dyntec Recent Developments
11.25 RVSRI
11.25.1 RVSRI Corporation Information
11.25.2 RVSRI Business Overview
11.25.3 RVSRI Veterinary Vaccine Product Models, Descriptions and Specifications
11.25.4 RVSRI Veterinary Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
11.25.5 RVSRI Recent Developments
11.26 Medion
11.26.1 Medion Corporation Information
11.26.2 Medion Business Overview
11.26.3 Medion Veterinary Vaccine Product Models, Descriptions and Specifications
11.26.4 Medion Veterinary Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
11.26.5 Medion Recent Developments

12 Value Chain and Supply-Chain Analysis
12.1 Veterinary Vaccine Industry Chain
12.2 Veterinary Vaccine Upstream Materials Analysis
12.2.1 Raw Materials
12.2.2 Key Suppliers Market Share & Risk Assessment
12.3 Veterinary Vaccine Integrated Production Analysis
12.3.1 Manufacturing Footprint Analysis
12.3.2 Regional Production Market Share (2021-2032)
12.3.3 Regulatory and Trade Policy Impact on Production
12.3.4 Production Technology Overview
12.3.5 Regional Cost Drivers
12.4 Veterinary Vaccine Sales Channels and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors

13 Veterinary Vaccine Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
13.4 Impact of U.S. Tariffs

14 Key Findings in the Global Veterinary Vaccine Study

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details

ページTOPに戻る

List of Tables/Graphs

List of Tables
Table 1. Global Veterinary Vaccine Market Size Growth Rate by Type, 2021 vs 2025 vs 2032 (US$ Million)
Table 2. Global Veterinary Vaccine Market Size Growth Rate by Target Pathogen, 2021 vs 2025 vs 2032 (US$ Million)
Table 3. Global Veterinary Vaccine Market Size Growth Rate by Antigen Composition, 2021 vs 2025 vs 2032 (US$ Million)
Table 4. Global Veterinary Vaccine Market Size Growth Rate by Application, 2021 vs 2025 vs 2032 (US$ Million)
Table 5. Global Veterinary Vaccine Revenue Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 6. Global Veterinary Vaccine Revenue by Region (US$ Million), 2021-2026
Table 7. Global Veterinary Vaccine Revenue by Region (US$ Million), 2027-2032
Table 8. Global Veterinary Vaccine Sales Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (M Doses)
Table 9. Global Veterinary Vaccine Sales by Region (M Doses), 2021-2026
Table 10. Global Veterinary Vaccine Sales by Region (M Doses), 2027-2032
Table 11. Emerging Market Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 12. Global Veterinary Vaccine Sales by Manufacturers (M Doses), 2021-2026
Table 13. Global Veterinary Vaccine Sales Share by Manufacturers (2021-2026)
Table 14. Global Veterinary Vaccine Revenue by Manufacturers (US$ Million), 2021-2026
Table 15. Global Veterinary Vaccine Revenue-Based Market Share by Manufacturers (2021-2026)
Table 16. Global Key Manufacturers’Ranking Shift (2024 vs. 2025) (Based on Revenue)
Table 17. Global Manufacturer by Tier (Tier 1, Tier 2, and Tier 3), based on Veterinary Vaccine Revenue, 2025
Table 18. Global Veterinary Vaccine Average Gross Margin (%) by Manufacturer (2021 vs 2025)
Table 19. Global Veterinary Vaccine Average Selling Price (ASP) by Manufacturers (USD/K Doses), 2021-2026
Table 20. Key Manufacturers Veterinary Vaccine Manufacturing Base and Headquarters
Table 21. Global Veterinary Vaccine Market Concentration Ratio (CR5)
Table 22. Key Market Entrant/Exit (2021-2025) – Drivers & Impact Analysis
Table 23. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 24. Global Veterinary Vaccine Sales Volume by Type (M Doses), 2021-2026
Table 25. Global Veterinary Vaccine Sales Volume by Type (M Doses), 2027-2032
Table 26. Global Veterinary Vaccine Revenue by Type (US$ Million), 2021-2026
Table 27. Global Veterinary Vaccine Revenue by Type (US$ Million), 2027-2032
Table 28. Global Veterinary Vaccine Sales Volume by Target Pathogen (M Doses), 2021-2026
Table 29. Global Veterinary Vaccine Sales Volume by Target Pathogen (M Doses), 2027-2032
Table 30. Global Veterinary Vaccine Revenue by Target Pathogen (US$ Million), 2021-2026
Table 31. Global Veterinary Vaccine Revenue by Target Pathogen (US$ Million), 2027-2032
Table 32. Global Veterinary Vaccine Sales Volume by Antigen Composition (M Doses), 2021-2026
Table 33. Global Veterinary Vaccine Sales Volume by Antigen Composition (M Doses), 2027-2032
Table 34. Global Veterinary Vaccine Revenue by Antigen Composition (US$ Million), 2021-2026
Table 35. Global Veterinary Vaccine Revenue by Antigen Composition (US$ Million), 2027-2032
Table 36. Technical Specifications by Key Product Type
Table 37. Global Veterinary Vaccine Sales by Application (M Doses), 2021-2026
Table 38. Global Veterinary Vaccine Sales by Application (M Doses), 2027-2032
Table 39. Veterinary Vaccine High-Growth Sectors Demand CAGR (2026-2032)
Table 40. Global Veterinary Vaccine Revenue by Application (US$ Million), 2021-2026
Table 41. Global Veterinary Vaccine Revenue by Application (US$ Million), 2027-2032
Table 42. Top Customers by Region
Table 43. Top Customers by Application
Table 44. North America Veterinary Vaccine Growth Accelerators and Market Barriers
Table 45. North America Veterinary Vaccine Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 46. North America Veterinary Vaccine Sales (M Doses) by Country (2021 vs 2025 vs 2032)
Table 47. Europe Veterinary Vaccine Growth Accelerators and Market Barriers
Table 48. Europe Veterinary Vaccine Revenue Grow Rate (CAGR) by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 49. Europe Veterinary Vaccine Sales (M Doses) by Country (2021 vs 2025 vs 2032)
Table 50. Asia-Pacific Veterinary Vaccine Revenue Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 51. Asia-Pacific Veterinary Vaccine Sales (M Doses) by Country (2021 vs 2025 vs 2032)
Table 52. Asia-Pacific Veterinary Vaccine Growth Accelerators and Market Barriers
Table 53. Southeast Asia Veterinary Vaccine Revenue Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 54. Central and South America Veterinary Vaccine Investment Opportunities and Key Challenges
Table 55. Central and South America Veterinary Vaccine Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 56. Middle East and Africa Veterinary Vaccine Investment Opportunities and Key Challenges
Table 57. Middle East and Africa Veterinary Vaccine Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 58. Merck Corporation Information
Table 59. Merck Description and Major Businesses
Table 60. Merck Product Models, Descriptions and Specifications
Table 61. Merck Sales (M Doses), Revenue (US$ Million), Price (USD/K Doses) and Gross Margin (2021-2026)
Table 62. Merck Sales Value Proportion by Product in 2025
Table 63. Merck Sales Value Proportion by Application in 2025
Table 64. Merck Sales Value Proportion by Geographic Area in 2025
Table 65. Merck Veterinary Vaccine SWOT Analysis
Table 66. Merck Recent Developments
Table 67. Zoetis Corporation Information
Table 68. Zoetis Description and Major Businesses
Table 69. Zoetis Product Models, Descriptions and Specifications
Table 70. Zoetis Sales (M Doses), Revenue (US$ Million), Price (USD/K Doses) and Gross Margin (2021-2026)
Table 71. Zoetis Sales Value Proportion by Product in 2025
Table 72. Zoetis Sales Value Proportion by Application in 2025
Table 73. Zoetis Sales Value Proportion by Geographic Area in 2025
Table 74. Zoetis Veterinary Vaccine SWOT Analysis
Table 75. Zoetis Recent Developments
Table 76. Boehringer Ingelheim Corporation Information
Table 77. Boehringer Ingelheim Description and Major Businesses
Table 78. Boehringer Ingelheim Product Models, Descriptions and Specifications
Table 79. Boehringer Ingelheim Sales (M Doses), Revenue (US$ Million), Price (USD/K Doses) and Gross Margin (2021-2026)
Table 80. Boehringer Ingelheim Sales Value Proportion by Product in 2025
Table 81. Boehringer Ingelheim Sales Value Proportion by Application in 2025
Table 82. Boehringer Ingelheim Sales Value Proportion by Geographic Area in 2025
Table 83. Boehringer Ingelheim Veterinary Vaccine SWOT Analysis
Table 84. Boehringer Ingelheim Recent Developments
Table 85. Ceva Corporation Information
Table 86. Ceva Description and Major Businesses
Table 87. Ceva Product Models, Descriptions and Specifications
Table 88. Ceva Sales (M Doses), Revenue (US$ Million), Price (USD/K Doses) and Gross Margin (2021-2026)
Table 89. Ceva Sales Value Proportion by Product in 2025
Table 90. Ceva Sales Value Proportion by Application in 2025
Table 91. Ceva Sales Value Proportion by Geographic Area in 2025
Table 92. Ceva Veterinary Vaccine SWOT Analysis
Table 93. Ceva Recent Developments
Table 94. CAHIC Corporation Information
Table 95. CAHIC Description and Major Businesses
Table 96. CAHIC Product Models, Descriptions and Specifications
Table 97. CAHIC Sales (M Doses), Revenue (US$ Million), Price (USD/K Doses) and Gross Margin (2021-2026)
Table 98. CAHIC Sales Value Proportion by Product in 2025
Table 99. CAHIC Sales Value Proportion by Application in 2025
Table 100. CAHIC Sales Value Proportion by Geographic Area in 2025
Table 101. CAHIC Veterinary Vaccine SWOT Analysis
Table 102. CAHIC Recent Developments
Table 103. HVRI Corporation Information
Table 104. HVRI Description and Major Businesses
Table 105. HVRI Product Models, Descriptions and Specifications
Table 106. HVRI Sales (M Doses), Revenue (US$ Million), Price (USD/K Doses) and Gross Margin (2021-2026)
Table 107. HVRI Recent Developments
Table 108. Ringpu Biology Corporation Information
Table 109. Ringpu Biology Description and Major Businesses
Table 110. Ringpu Biology Product Models, Descriptions and Specifications
Table 111. Ringpu Biology Sales (M Doses), Revenue (US$ Million), Price (USD/K Doses) and Gross Margin (2021-2026)
Table 112. Ringpu Biology Recent Developments
Table 113. Yebio Corporation Information
Table 114. Yebio Description and Major Businesses
Table 115. Yebio Product Models, Descriptions and Specifications
Table 116. Yebio Sales (M Doses), Revenue (US$ Million), Price (USD/K Doses) and Gross Margin (2021-2026)
Table 117. Yebio Recent Developments
Table 118. DHN Corporation Information
Table 119. DHN Description and Major Businesses
Table 120. DHN Product Models, Descriptions and Specifications
Table 121. DHN Sales (M Doses), Revenue (US$ Million), Price (USD/K Doses) and Gross Margin (2021-2026)
Table 122. DHN Recent Developments
Table 123. WINSUN Corporation Information
Table 124. WINSUN Description and Major Businesses
Table 125. WINSUN Product Models, Descriptions and Specifications
Table 126. WINSUN Sales (M Doses), Revenue (US$ Million), Price (USD/K Doses) and Gross Margin (2021-2026)
Table 127. WINSUN Recent Developments
Table 128. Elanco Corporation Information
Table 129. Elanco Description and Major Businesses
Table 130. Elanco Product Models, Descriptions and Specifications
Table 131. Elanco Sales (M Doses), Revenue (US$ Million), Price (USD/K Doses) and Gross Margin (2021-2026)
Table 132. Elanco Recent Developments
Table 133. Virbac Corporation Information
Table 134. Virbac Description and Major Businesses
Table 135. Virbac Product Models, Descriptions and Specifications
Table 136. Virbac Sales (M Doses), Revenue (US$ Million), Price (USD/K Doses) and Gross Margin (2021-2026)
Table 137. Virbac Recent Developments
Table 138. Jinyu Bio-Technology Corporation Information
Table 139. Jinyu Bio-Technology Description and Major Businesses
Table 140. Jinyu Bio-Technology Product Models, Descriptions and Specifications
Table 141. Jinyu Bio-Technology Sales (M Doses), Revenue (US$ Million), Price (USD/K Doses) and Gross Margin (2021-2026)
Table 142. Jinyu Bio-Technology Recent Developments
Table 143. ChengDu Tecbond Corporation Information
Table 144. ChengDu Tecbond Description and Major Businesses
Table 145. ChengDu Tecbond Product Models, Descriptions and Specifications
Table 146. ChengDu Tecbond Sales (M Doses), Revenue (US$ Million), Price (USD/K Doses) and Gross Margin (2021-2026)
Table 147. ChengDu Tecbond Recent Developments
Table 148. CAVAC Corporation Information
Table 149. CAVAC Description and Major Businesses
Table 150. CAVAC Product Models, Descriptions and Specifications
Table 151. CAVAC Sales (M Doses), Revenue (US$ Million), Price (USD/K Doses) and Gross Margin (2021-2026)
Table 152. CAVAC Recent Developments
Table 153. Kyoto Biken Laboratories Corporation Information
Table 154. Kyoto Biken Laboratories Description and Major Businesses
Table 155. Kyoto Biken Laboratories Product Models, Descriptions and Specifications
Table 156. Kyoto Biken Laboratories Sales (M Doses), Revenue (US$ Million), Price (USD/K Doses) and Gross Margin (2021-2026)
Table 157. Kyoto Biken Laboratories Recent Developments
Table 158. FATRO Corporation Information
Table 159. FATRO Description and Major Businesses
Table 160. FATRO Product Models, Descriptions and Specifications
Table 161. FATRO Sales (M Doses), Revenue (US$ Million), Price (USD/K Doses) and Gross Margin (2021-2026)
Table 162. FATRO Recent Developments
Table 163. Vaksindo Corporation Information
Table 164. Vaksindo Description and Major Businesses
Table 165. Vaksindo Product Models, Descriptions and Specifications
Table 166. Vaksindo Sales (M Doses), Revenue (US$ Million), Price (USD/K Doses) and Gross Margin (2021-2026)
Table 167. Vaksindo Recent Developments
Table 168. Bio-Labs Corporation Information
Table 169. Bio-Labs Description and Major Businesses
Table 170. Bio-Labs Product Models, Descriptions and Specifications
Table 171. Bio-Labs Sales (M Doses), Revenue (US$ Million), Price (USD/K Doses) and Gross Margin (2021-2026)
Table 172. Bio-Labs Recent Developments
Table 173. Avimex Animal Health Corporation Information
Table 174. Avimex Animal Health Description and Major Businesses
Table 175. Avimex Animal Health Product Models, Descriptions and Specifications
Table 176. Avimex Animal Health Sales (M Doses), Revenue (US$ Million), Price (USD/K Doses) and Gross Margin (2021-2026)
Table 177. Avimex Animal Health Recent Developments
Table 178. MEVAC Corporation Information
Table 179. MEVAC Description and Major Businesses
Table 180. MEVAC Product Models, Descriptions and Specifications
Table 181. MEVAC Sales (M Doses), Revenue (US$ Million), Price (USD/K Doses) and Gross Margin (2021-2026)
Table 182. MEVAC Recent Developments
Table 183. Biovac Corporation Information
Table 184. Biovac Description and Major Businesses
Table 185. Biovac Product Models, Descriptions and Specifications
Table 186. Biovac Sales (M Doses), Revenue (US$ Million), Price (USD/K Doses) and Gross Margin (2021-2026)
Table 187. Biovac Recent Developments
Table 188. Atafen Corporation Information
Table 189. Atafen Description and Major Businesses
Table 190. Atafen Product Models, Descriptions and Specifications
Table 191. Atafen Sales (M Doses), Revenue (US$ Million), Price (USD/K Doses) and Gross Margin (2021-2026)
Table 192. Atafen Recent Developments
Table 193. Dyntec Corporation Information
Table 194. Dyntec Description and Major Businesses
Table 195. Dyntec Product Models, Descriptions and Specifications
Table 196. Dyntec Sales (M Doses), Revenue (US$ Million), Price (USD/K Doses) and Gross Margin (2021-2026)
Table 197. Dyntec Recent Developments
Table 198. RVSRI Corporation Information
Table 199. RVSRI Description and Major Businesses
Table 200. RVSRI Product Models, Descriptions and Specifications
Table 201. RVSRI Sales (M Doses), Revenue (US$ Million), Price (USD/K Doses) and Gross Margin (2021-2026)
Table 202. RVSRI Recent Developments
Table 203. Medion Corporation Information
Table 204. Medion Description and Major Businesses
Table 205. Medion Product Models, Descriptions and Specifications
Table 206. Medion Sales (M Doses), Revenue (US$ Million), Price (USD/K Doses) and Gross Margin (2021-2026)
Table 207. Medion Recent Developments
Table 208. Key Raw Materials Distribution
Table 209. Raw Materials Key Suppliers
Table 210. Critical Raw Material Supplier Concentration (2025) & Risk Index
Table 211. Milestones in Production Technology Evolution
Table 212. Distributors List
Table 213. Market Trends and Market Evolution
Table 214. Market Drivers and Opportunities
Table 215. Market Challenges, Risks, and Restraints
Table 216. Research Programs/Design for This Report
Table 217. Key Data Information from Secondary Sources
Table 218. Key Data Information from Primary Sources

List of Figures
Figure 1. Veterinary Vaccine Product Picture
Figure 2. Global Veterinary Vaccine Market Size Growth Rate by Type, 2021 vs 2025 vs 2032 (US$ Million)
Figure 3. Live Attenuated Vaccines Product Picture
Figure 4. Inactivated Vaccines Product Picture
Figure 5. Other Product Picture
Figure 6. Global Veterinary Vaccine Market Size Growth Rate by Target Pathogen, 2021 vs 2025 vs 2032 (US$ Million)
Figure 7. Viral Vaccines Product Picture
Figure 8. Bacterial Vaccines Product Picture
Figure 9. Parasitic Vaccines Product Picture
Figure 10. Other Product Picture
Figure 11. Global Veterinary Vaccine Market Size Growth Rate by Antigen Composition, 2021 vs 2025 vs 2032 (US$ Million)
Figure 12. Monovalent Vaccines Product Picture
Figure 13. Multivalent Vaccines Product Picture
Figure 14. Combination Vaccines Product Picture
Figure 15. Global Veterinary Vaccine Market Size Growth Rate by Application, 2021 vs 2025 vs 2032 (US$ Million)
Figure 16. Farm Animal
Figure 17. Companion Animal
Figure 18. Veterinary Vaccine Report Years Considered
Figure 19. Global Veterinary Vaccine Revenue, (US$ Million), 2021 vs 2025 vs 2032
Figure 20. Global Veterinary Vaccine Revenue (US$ Million), 2021-2032
Figure 21. Global Veterinary Vaccine Revenue (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Figure 22. Global Veterinary Vaccine Revenue-Based Market Share by Region (2021-2032)
Figure 23. Global Veterinary Vaccine Sales (M Doses), 2021-2032
Figure 24. Global Veterinary Vaccine Sales (CAGR) by Region: 2021 vs 2025 vs 2032 (M Doses)
Figure 25. Global Veterinary Vaccine Sales Market Share by Region (2021-2032)
Figure 26. Top 5 and Top 10 Manufacturers Veterinary Vaccine Sales Volume Market Share in 2025
Figure 27. Global Veterinary Vaccine Revenue-Based Market Share Ranking (2025)
Figure 28. Tier Distribution by Revenue Contribution (2021 vs 2025)
Figure 29. Live Attenuated Vaccines Revenue-Based Market Share by Manufacturer in 2025
Figure 30. Inactivated Vaccines Revenue-Based Market Share by Manufacturer in 2025
Figure 31. Other Revenue-Based Market Share by Manufacturer in 2025
Figure 32. Global Veterinary Vaccine Sales Volume-Based Market Share by Type (2021-2032)
Figure 33. Global Veterinary Vaccine Revenue-Based Market Share by Type (2021-2032)
Figure 34. Global Veterinary Vaccine ASP by Type (USD/K Doses), 2021-2032
Figure 35. Global Veterinary Vaccine Sales Volume-Based Market Share by Target Pathogen (2021-2032)
Figure 36. Global Veterinary Vaccine Revenue-Based Market Share by Target Pathogen (2021-2032)
Figure 37. Global Veterinary Vaccine ASP by Target Pathogen (USD/K Doses), 2021-2032
Figure 38. Global Veterinary Vaccine Sales Volume-Based Market Share by Antigen Composition (2021-2032)
Figure 39. Global Veterinary Vaccine Revenue-Based Market Share by Antigen Composition (2021-2032)
Figure 40. Global Veterinary Vaccine ASP by Antigen Composition (USD/K Doses), 2021-2032
Figure 41. Global Veterinary Vaccine Sales Market Share by Application (2021-2032)
Figure 42. Global Veterinary Vaccine Revenue-Based Market Share by Application (2021-2032)
Figure 43. Global Veterinary Vaccine ASP by Application (USD/K Doses), 2021-2032
Figure 44. North America Veterinary Vaccine Sales YoY (M Doses), 2021-2032
Figure 45. North America Veterinary Vaccine Revenue YoY (US$ Million), 2021-2032
Figure 46. North America Top 5 Manufacturers Veterinary Vaccine Sales Revenue (US$ Million) in 2025
Figure 47. North America Veterinary Vaccine Sales Volume (M Doses) by Application (2021-2032)
Figure 48. North America Veterinary Vaccine Sales Revenue (US$ Million) by Application (2021-2032)
Figure 49. US Veterinary Vaccine Revenue (US$ Million), 2021-2032
Figure 50. Canada Veterinary Vaccine Revenue (US$ Million), 2021-2032
Figure 51. Mexico Veterinary Vaccine Revenue (US$ Million), 2021-2032
Figure 52. Europe Veterinary Vaccine Sales YoY (M Doses), 2021-2032
Figure 53. Europe Veterinary Vaccine Revenue YoY (US$ Million), 2021-2032
Figure 54. Europe Top 5 Manufacturers Veterinary Vaccine Sales Revenue (US$ Million) in 2025
Figure 55. Europe Veterinary Vaccine Sales Volume (M Doses) by Application (2021-2032)
Figure 56. Europe Veterinary Vaccine Sales Revenue (US$ Million) by Application (2021-2032)
Figure 57. Germany Veterinary Vaccine Revenue (US$ Million), 2021-2032
Figure 58. France Veterinary Vaccine Revenue (US$ Million), 2021-2032
Figure 59. U.K. Veterinary Vaccine Revenue (US$ Million), 2021-2032
Figure 60. Italy Veterinary Vaccine Revenue (US$ Million), 2021-2032
Figure 61. Russia Veterinary Vaccine Revenue (US$ Million), 2021-2032
Figure 62. Greece Veterinary Vaccine Revenue (US$ Million), 2021-2032
Figure 63. Ukraine Veterinary Vaccine Revenue (US$ Million), 2021-2032
Figure 64. Moldova Veterinary Vaccine Revenue (US$ Million), 2021-2032
Figure 65. Albania Veterinary Vaccine Revenue (US$ Million), 2021-2032
Figure 66. Serbia Veterinary Vaccine Revenue (US$ Million), 2021-2032
Figure 67. Asia-Pacific Veterinary Vaccine Sales YoY (M Doses), 2021-2032
Figure 68. Asia-Pacific Veterinary Vaccine Revenue YoY (US$ Million), 2021-2032
Figure 69. Asia-Pacific Top 8 Manufacturers Veterinary Vaccine Sales Revenue (US$ Million) in 2025
Figure 70. Asia-Pacific Veterinary Vaccine Sales Volume (M Doses) by Application (2021-2032)
Figure 71. Asia-Pacific Veterinary Vaccine Sales Revenue (US$ Million) by Application (2021-2032)
Figure 72. Indonesia Veterinary Vaccine Revenue (US$ Million), 2021-2032
Figure 73. Japan Veterinary Vaccine Revenue (US$ Million), 2021-2032
Figure 74. South Korea Veterinary Vaccine Revenue (US$ Million), 2021-2032
Figure 75. China Taiwan Veterinary Vaccine Revenue (US$ Million), 2021-2032
Figure 76. India Veterinary Vaccine Revenue (US$ Million), 2021-2032
Figure 77. Central and South America Veterinary Vaccine Sales YoY (M Doses), 2021-2032
Figure 78. Central and South America Veterinary Vaccine Revenue YoY (US$ Million), 2021-2032
Figure 79. Central and South America Top 5 Manufacturers Veterinary Vaccine Sales Revenue (US$ Million) in 2025
Figure 80. Central and South America Veterinary Vaccine Sales Volume (M Doses) by Application (2021-2032)
Figure 81. Central and South America Veterinary Vaccine Sales Revenue (US$ Million) by Application (2021-2032)
Figure 82. Brazil Veterinary Vaccine Revenue (US$ Million), 2021-2032
Figure 83. Argentina Veterinary Vaccine Revenue (US$ Million), 2021-2032
Figure 84. Middle East, and Africa Veterinary Vaccine Sales YoY (M Doses), 2021-2032
Figure 85. Middle East and Africa Veterinary Vaccine Revenue YoY (US$ Million), 2021-2032
Figure 86. Middle East and Africa Top 5 Manufacturers Veterinary Vaccine Sales Revenue (US$ Million) in 2025
Figure 87. Middle East and Africa Veterinary Vaccine Sales Volume (M Doses) by Application (2021-2032)
Figure 88. Middle East and Africa Veterinary Vaccine Sales Revenue (US$ Million) by Application (2021-2032)
Figure 89. GCC Countries Veterinary Vaccine Revenue (US$ Million), 2021-2032
Figure 90. Turkey Veterinary Vaccine Revenue (US$ Million), 2021-2032
Figure 91. Egypt Veterinary Vaccine Revenue (US$ Million), 2021-2032
Figure 92. South Africa Veterinary Vaccine Revenue (US$ Million), 2021-2032
Figure 93. Veterinary Vaccine Industry Chain Mapping
Figure 94. Regional Veterinary Vaccine Manufacturing Base Distribution (%)
Figure 95. Global Veterinary Vaccine Production Market Share by Region (2021-2032)
Figure 96. Veterinary Vaccine Production Process
Figure 97. Regional Veterinary Vaccine Production Cost Structure
Figure 98. Channels of Distribution (Direct Vs Distribution)
Figure 99. Bottom-up and Top-down Approaches for This Report
Figure 100. Data Triangulation
Figure 101. Key Executives Interviewed